Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO) and Applied DNA Sciences (NASDAQ: APDN)
Allogene Therapeutics (ALLO) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics, with a price target of $43.00. The company’s shares closed last Wednesday at $35.12. According to TipRanks.com, Burns is a 4-star analyst with an average return of 15.5% and a 44.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics. The wor...
Yi Chen Robert Burns Interpace Diagnostics Group Ortho Clinical Diagnostics Holdings Forma Therapeutics Holdings Allogene Therapeutics
Source: analystratings.com